Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy

[thumbnail of Publisher's Version]
Preview
PDF (Publisher's Version) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB

Item Type:Review
Title:Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy
Creators Name:Wirth, M., Schick, M., Keller, U. and Krönke, J.
Abstract:Multiple myeloma is a genetically heterogeneous plasma cell malignancy characterized by organ damage and a massive production of (in-)complete monoclonal antibodies. Coping with protein homeostasis and post-translational regulation is therefore essential for multiple myeloma cells to survive. Furthermore, post-translational modifications such as ubiquitination and SUMOylation play key roles in essential pathways in multiple myeloma, including NFκB signaling, epigenetic regulation, as well as DNA damage repair. Drugs modulating the ubiquitin-proteasome system, such as proteasome inhibitors and thalidomide analogs, are approved and highly effective drugs in multiple myeloma. In this review, we focus on ubiquitin and ubiquitin-like modifications in the biology and current developments of new treatments for multiple myeloma.
Keywords:Multiple Myeloma, SUMO, NEDD, Ubiquitin, PROTAC, Proteasome, IMiD
Source:Cancers
ISSN:2072-6694
Publisher:MDPI
Volume:12
Number:12
Page Range:3764
Date:14 December 2020
Official Publication:https://doi.org/10.3390/cancers12123764
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library